X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs DR. REDDYS LAB - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON DR. REDDYS LAB BIOCON /
DR. REDDYS LAB
 
P/E (TTM) x 19.3 23.1 83.6% View Chart
P/BV x 3.0 3.2 96.6% View Chart
Dividend Yield % 0.4 0.8 50.7%  

Financials

 BIOCON    DR. REDDYS LAB
EQUITY SHARE DATA
    BIOCON
Mar-18
DR. REDDYS LAB
Mar-19
BIOCON /
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,1882,875 41.3%   
Low Rs3051,888 16.2%   
Sales per share (Unadj.) Rs68.7930.2 7.4%  
Earnings per share (Unadj.) Rs7.6117.4 6.4%  
Cash flow per share (Unadj.) Rs14.0185.8 7.5%  
Dividends per share (Unadj.) Rs1.0020.00 5.0%  
Dividend yield (eoy) %0.10.8 16.0%  
Book value per share (Unadj.) Rs86.3844.4 10.2%  
Shares outstanding (eoy) m600.00166.07 361.3%   
Bonus/Rights/Conversions ISESOP-  
Price / Sales ratio x10.92.6 424.3%   
Avg P/E ratio x98.920.3 487.4%  
P/CF ratio (eoy) x53.412.8 416.8%  
Price / Book Value ratio x8.62.8 306.6%  
Dividend payout %13.217.0 77.7%   
Avg Mkt Cap Rs m447,900395,496 113.3%   
No. of employees `0006.122.0 28.0%   
Total wages/salary Rs m9,31133,562 27.7%   
Avg. sales/employee Rs Th6,705.87,032.8 95.4%   
Avg. wages/employee Rs Th1,514.21,527.9 99.1%   
Avg. net profit/employee Rs Th736.9887.7 83.0%   
INCOME DATA
Net Sales Rs m41,234154,482 26.7%  
Other income Rs m2,0623,375 61.1%   
Total revenues Rs m43,296157,857 27.4%   
Gross profit Rs m8,29131,782 26.1%  
Depreciation Rs m3,85111,348 33.9%   
Interest Rs m615889 69.2%   
Profit before tax Rs m5,88722,920 25.7%   
Minority Interest Rs m2130-   
Prior Period Items Rs m0438 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5693,858 40.7%   
Profit after tax Rs m4,53119,500 23.2%  
Gross profit margin %20.120.6 97.7%  
Effective tax rate %26.716.8 158.3%   
Net profit margin %11.012.6 87.1%  
BALANCE SHEET DATA
Current assets Rs m41,486111,101 37.3%   
Current liabilities Rs m21,41358,973 36.3%   
Net working cap to sales %48.733.7 144.3%  
Current ratio x1.91.9 102.8%  
Inventory Days Days6479 80.6%  
Debtors Days Days9494 100.0%  
Net fixed assets Rs m50,661101,245 50.0%   
Share capital Rs m3,000830 361.4%   
"Free" reserves Rs m48,808139,406 35.0%   
Net worth Rs m51,808140,236 36.9%   
Long term debt Rs m17,89822,000 81.4%   
Total assets Rs m99,897224,656 44.5%  
Interest coverage x10.626.8 39.5%   
Debt to equity ratio x0.30.2 220.2%  
Sales to assets ratio x0.40.7 60.0%   
Return on assets %5.29.1 56.8%  
Return on equity %8.713.9 62.9%  
Return on capital %9.614.9 64.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,05888,673 13.6%   
Fx outflow Rs m7,34819,104 38.5%   
Net fx Rs m4,71069,569 6.8%   
CASH FLOW
From Operations Rs m6,62128,704 23.1%  
From Investments Rs m-6,840-7,727 88.5%  
From Financial Activity Rs m-2,397-21,326 11.2%  
Net Cashflow Rs m-2,612-314 831.8%  

Share Holding

Indian Promoters % 40.4 25.5 158.4%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 5.4 155.6%  
FIIs % 10.7 35.3 30.3%  
ADR/GDR % 0.0 18.5 -  
Free float % 19.9 15.3 130.1%  
Shareholders   109,995 75,885 144.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   ELDER PHARMA  FDC LTD.  SHASUN PHARMA  STRIDES PHARMA SCIENCE  J.B.CHEMICALS  

Compare BIOCON With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End on a Positive Note for Third Straight Day; Yes Bank Falls 5%(Closing)

Indian share markets traded on a positive note most of the day and ended marginally higher. Sectoral indices ended on a mixed note with stocks in the IT sector.

Related Views on News

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

A One Stock Crorepati(Profit Hunter)

Jul 4, 2019

Do you wish you could become a crorepati in the stock market? Read on...

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jul 17, 2019 (Close)

TRACK BIOCON

BIOCON - PANACEA BIOTECH COMPARISON

COMPARE BIOCON WITH

MARKET STATS